The C25 index, Denmark’s benchmark for its largest listed companies, rose 1.61% in Wednesday’s trading session, marking a notable rebound for the market.
Ambu emerged as the top performer among the index constituents, leading the broader rally that helped offset recent selling pressure.
Zealand Pharma, Coloplast, and Ambu have each shed more than 30% of their market value since the start of the year, representing a significant underperformance relative to the broader market.
The positive session follows a difficult first half of 2026 for several heavyweight names in the index.
Zealand Pharma, Coloplast, and Ambu have each shed more than 30% of their market value since the start of the year, representing a significant underperformance relative to the broader market.
The steep declines have weighed heavily on investor sentiment, with some market participants expressing caution about the near-term outlook for these healthcare and medical technology leaders.
Despite the heavy losses for these three firms, the C25 index has seen divergent performance among its constituents.